bringing energy to life

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease.

 

khondrion

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Based on proprietary science and a deep understanding of mitochondrial dysfunction, the company is advancing its wholly owned lead drug candidate sonlicromanol for the treatment of both children and adults.  

Khondrion to Present Promising Advances in Mitochondrial Disease Therapy at Bio-Europe and Investival Showcase Events

NIJMEGEN, The Netherlands – October 29, 2024: Khondrion, a pioneering clinical-stage biopharmaceutical company focused...

Khondrion to present at Mitocon’s 14th Mitochondrial Disease Conference

NIJMEGEN, the Netherlands – 9 October, 2024: Khondrion, a clinical-stage biopharmaceutical company discovering and...

Khondrion appoints Jasper Levink as Chief Financial and Business Officer

NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutical company discovering and...

EuroHealth Leaders Magazine interviewed Khondrion’s CEO Jan Smeitink

Jan Smeitink: Serving the Mitochondrial Medicine Mission Embarking on the journey of biopharmaceutical innovation...

Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1

Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the...

Khondrion to participate in the 16th Annual Dutch Inborn Error Meeting and the United Mitochondrial Disease Foundation (UMDF) Bench to Bedside seminar

Khondrion to participate in the 16th Annual Dutch Inborn Error Meeting and the United Mitochondrial Disease Foundation...

Khondrion joins the NADIS International Student Training Network

Khondrion has joined a recently established consortium of universities and industry partners to train international...

2022 – A Year in Review

2022 – A Year in Review As 2022 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the significant progress...

Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders

Sonlicromanol for MELAS spectrum disorders – a rare, progressive primary mitochondrial disease – to move into a Phase...

Patient Perspective: A conversation with Kate Murray – CEO and President, MitoCanada

How did you first become involved with the mitochondrial disease community and MitoCanada? I joined MitoCanada at a...

working with others

At Khondrion we know that working in collaboration with others is important to accelerate the development of innovative new medicines. That is why we are pursuing cutting edge science both within our own labs and through partnerships across an extensive academic and industry network of experts and are sharing knowledge around mitochondrial disease in close collaboration with patient organizations to help develop important new medicines and treatments for patients.

“the solution is within our reach”

Since 2012 Khondrion has been progressing a pipeline with the potential to deliver transformative medicines for patients living with mitochondrial disease.

get in touch

Whether you are a researcher, job seeker, health professional, patient, potential investor or potential business partner, you can contact us using this form.